Combined Vaccine (Hib+MMR)
Haemophilus influenzae type b, Measles, Mumps, Rubella Prevention
Key Facts
Indication
Haemophilus influenzae type b, Measles, Mumps, Rubella Prevention
Phase
Phase I
Status
Active
Company
About Sinovac Biotech
Sinovac Biotech's mission is to supply vaccines to eliminate human infectious diseases worldwide. Its key achievement was the development and global distribution of CoronaVac, one of the most widely administered COVID-19 vaccines, which solidified its international standing and showcased its integrated manufacturing model. The company's strategy is anchored in its core inactivated vaccine technology platform, with a focus on expanding its pipeline for both endemic and pandemic threats while pursuing commercial partnerships in emerging markets. Financially, it faces the challenge of transitioning from peak pandemic revenue to a sustainable portfolio-driven growth model.
View full company profile